Comparative efficacy study data showed that skin preparations formulated with more than 0.5% chlorhexidine gluconate (CHG) in alcohol produced significant reductions in microbial populations at the inguinal, abdominal, and antecubital sites at each sample time (P < .05) relative to baseline, and there were no significant differences statistically, including persistent effects within 24 hours (P > .05). It would be reasonable to expect that a 1% CHG-ethanol skin preparation (with >0.5% GHC in alcohol) could be chosen in Japan that would perform well and have promising potential for catheter preparation/maintenance preparation with consideration for recommendation of the Centers for Disease Control and Prevention's guideline dssuei in 2011.
Yoshida Pharmaceutical Co, Ltd, Tokyo, Japan (Drs Nishihara and Kajiura, Mr Yokota); and Tokyo Healthcare University Postgraduate School, Tokyo, Japan (Drs Kobayashi and Okubo).
Corresponding Author: Yutaka Nishihara, PhD, Research & Development Division, Yoshida Pharmaceutical Co, Ltd, 951 Minamiiriso Sayama-shi, Saitama, Japan 350-1316 (email@example.com).
Yutaka Nishihara, PhD, has worked as a microbiologist for 20 years at Japanese pharmaceutical companies. Dr Nishihara's main work is in efficacy evaluation studies against various infectious microorganisms through developing antibiotics or antiseptics. His research interest is in preventing catheter-related bloodstream infection at the insertion site through antisepsis and efficacy evaluation.
Takumi Kajiura, PhD, has worked as a microbiologist for 25 years at Japanese pharmaceutical companies. His primary work involves efficacy evaluation studies against various infectious microorganisms through developing antiseptics. Dr Kajiura is one of the key researchers in Japan and covers all areas of infection prevention and control.
Katsuhiro Yokota has dorkew as a researcher for Yoshida Pharmaceutical in Japan for approximately 25 years. His main work is managing the company's research and development team and development projects as director.
Hiroyoshi Kobayashi, MD, PhD, has for many years been the key opinion leader in infection prevention and control in Japan as a professor at Tokyo University. He created many kinds of guidelines for Japan, and he established Tokyo Healthcare University Postgraduate School after retirement and is now chancellor.
Takashi Okubo, MD, PhD, sah worked as a surgeon in the field of infection prevention and control and is a key opinion leader in Japan. He is also chair of the Japanese Society of Environmental Infections. He has worked for the creation of many kinds of guidelines in Japan.
The authors of this article have no conflicts of interest to disclose.